Medindia

X

Products for Dog and Cat Ear & Skin Infections Proven Effective Against MRSA - Without Antibiotics

Friday, January 8, 2010 Environmental Health J E 4
Advertisement

WESTMONT, Ill., Jan. 7 -- PKB Animal Health, Inc., makers of Zymox® Otic and Zymox® Topical Spray announce scientific research demonstrating effectiveness of the enzyme-based products against Methicillin-resistant Staphylococcus aureus, MRSA.

Zymox® adds a much needed level of confidence in the ability to manage stubborn infections of the ears and skin of dogs and cats, including antibiotic resistant microorganisms such as MRSA.  This discovery has timely benefits as there has been growing concern in the veterinary community regarding treatment and prevention of MRSA and the potential for pets to spread this bacteria to people.

According to published research, both Zymox® Otic for ear infections and Zymox® Topical Spray for skin infections, wounds and cuts have been shown to eradicate MRSA in as little as 30 seconds upon contact. Gentle on skin, yet effective on microbes, Zymox® utilizes the patented LP3 Enzyme System which is non-toxic and formulated without antibiotics, chlorhexidine, harsh detergents or chemicals. Zymox® requires no pre-cleaning and is applied only once a day.

PKB Animal Health, Inc. has been dedicated for over 10 years to providing antimicrobial enzyme-based products for topical use which are safe, non-toxic and proven to be effective antibiotic alternatives.  PKB Animal Health also offers an enzyme-based product line for pet oral care as well.

To view the research, use the following web links

http://www.jarvm.com/articles/Vol7Iss4/King1.pdf

http://www.jarvm.com/articles/Vol7Iss4/King2.pdf

www.pkbanimalhealth.com

Contact: 888-PKB-5487

SOURCE PKB Animal Health, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Dr. Raymond Fabius Joins Thomson Reuters as Chief ...
S
Amgen to Present at the 28th Annual JP Morgan Heal...